Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects. After the announcement, Genentech's...
Genentech halted a clinical study yesterday after ovarian cancer patients suffered serious side effects.
After the announcement, Genentech’s shares fell. Avastin, approved for the treatment for colon cancer, was considered Genentech’s most promising drug.
Genentech said it stopped accepting participants in the ovarian cancer study after five of 44 patients suffered bowel tears.
The clinical trial was testing Avastin for ovarian cancer patients whose disease did not respond to chemotherapy drugs containing platinum.
Most Read Stories
- Seattle judge won’t immediately release ‘Dreamer’ from detention center
- Officials say damage to sewage plant in Discovery Park is catastrophic
- T-Mobile one-ups Verizon’s new unlimited data plan; 4Q results top forecasts
- Sticker shock as much higher car-tab bills land in mailboxes
- Students frustrated trying to get into UW’s strict engineering program
Jim Reddich, an analyst with Friedman, Billings, Ramsey, said that Avastin might not reach its peak sales potential of $7 billion if doctors became worried about safety. The drug is expected to have sales of $1 billion this year.
Shares of Genentech fell $2.17 to $85.83.